bioMérieux - Second-Quarter 2014 Business Review

• Solid growth in first-half sales
  
  • Up 7.9%, including BioFire and at constant exchange rates
  • Up 4.2% like-for-like*, in line with the target for the year
  • Up 3.5% on a reported basis
• Greater disparity between regions
  
  • Good sales momentum in North America
  • Business recovery confirmed in Europe
  • Slowdown in China
• 2014 objective of 3%-5% organic sales growth maintained
• Effective deployment of the new organization
• Significant progress on the integration of BioFire
  
  • Regulatory approval obtained for a third panel
  • Commercial availability of FilmArray® extended to new markets
  • Molecular biology sales including BioFire: up 70%

“bioMérieux reported solid growth in net sales in the first half of 2014,” said Chief Executive Officer Alexandre Mérieux. “Led by vigorous demand in North America and a markedly improved sales performance in Europe, organic growth came to 4.2% for the period, despite low sales in China. Following the consolidation of BioFire, which was acquired in mid-January 2014, overall growth totaled 7.9% at constant exchange rates. Backed by our new operating structure which, in particular, will help us to energize the process of executing our strategic plan and by the geographical diversification of our business model, we are confirming our organic sales growth objective for 2014.”

Marcy l'Etoile, France - July 17, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended June 30, 2014.

SALES

Sales ended the first half at €781 million, versus €754 million a year earlier, for a reported increase of 3.5%. Exchange rate fluctuations, primarily reflecting the rise in the euro against other currencies, resulted in a negative currency effect of €33 million, or 440 bps. In this environment, organic growth (at constant exchange rates and scope of consolidation) came to 4.2%. In addition, consolidated sales included the €28 million in sales generated by BioFire as from January 16, driving a 7.9% increase in sales at constant exchange rates.

* On an organic basis (at constant exchange rates and scope of consolidation)